22-Mar-2026 4:17 PM CST - Yahoo Finance How The Regeneron (REGN) Story Is Shifting As Dupixent And Pipeline Expectations Reset Regeneron Pharmaceuticals is back in focus after a refreshed valuation framework lifted the modelled fair value estimate from US$821.12 to US$873.78 per share, a step up that pushes implied targets closer to the high US$800s and low US$900s seen in recent research.
6-Mar-2026 7:00 AM CST - Benzinga Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $838.07, a high estimate of $975.00, and a low estimate of $745.00. This upward trend is evident, with the current average reflecting a 9.77% increase from the previous average price target of $763.46.
16-Feb-2026 1:01 PM CST - Benzinga Price Over Earnings Overview: Regeneron Pharmaceuticals In the current market session, Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock price is at $797.57, after a 0.70% drop. However, over the past month, the company's stock spiked by 9.46%, and in the past year,
13-Feb-2026 9:27 AM CST - Yahoo Finance Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10,
10-Feb-2026 5:22 PM CST - Yahoo Finance The Bull Case For Regeneron (REGN) Could Change Following New Allergy Antibody And Dupixent Data Unveiling Regeneron Pharmaceuticals recently outlined 36 upcoming presentations from its immunology and inflammation portfolio at the late-February 2026 AAAAI meeting, including first Phase 3 data on allergen-specific antibody cocktails for cat and birch allergies and new Dupixent analyses across multiple diseases.
6-Feb-2026 11:38 AM CST - Yahoo Finance A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Pullback Has Been Trading Recently Regeneron Pharmaceuticals (REGN) has been moving within a mixed performance range, with a 1 day return of about a 1% decline, a 7 day gain of 3.4%, a month decline of 5.6%, and a past 3 months gain of 16.
Latest REGN Trades by Congress Members
12-FEB-2026 - Julia Letlow, LA (District 5) purchased between $1,001 and $15,000.
22-Mar-2026 4:17 PM CST - Yahoo Finance How The Regeneron (REGN) Story Is Shifting As Dupixent And Pipeline Expectations Reset Regeneron Pharmaceuticals is back in focus after a refreshed valuation framework lifted the modelled fair value estimate from US$821.12 to US$873.78 per share, a step up that pushes implied targets closer to the high US$800s and low US$900s seen in recent research.
6-Mar-2026 7:00 AM CST - Benzinga Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $838.07, a high estimate of $975.00, and a low estimate of $745.00. This upward trend is evident, with the current average reflecting a 9.77% increase from the previous average price target of $763.46.
16-Feb-2026 1:01 PM CST - Benzinga Price Over Earnings Overview: Regeneron Pharmaceuticals In the current market session, Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock price is at $797.57, after a 0.70% drop. However, over the past month, the company's stock spiked by 9.46%, and in the past year,
13-Feb-2026 9:27 AM CST - Yahoo Finance Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10,
10-Feb-2026 5:22 PM CST - Yahoo Finance The Bull Case For Regeneron (REGN) Could Change Following New Allergy Antibody And Dupixent Data Unveiling Regeneron Pharmaceuticals recently outlined 36 upcoming presentations from its immunology and inflammation portfolio at the late-February 2026 AAAAI meeting, including first Phase 3 data on allergen-specific antibody cocktails for cat and birch allergies and new Dupixent analyses across multiple diseases.
6-Feb-2026 11:38 AM CST - Yahoo Finance A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Pullback Has Been Trading Recently Regeneron Pharmaceuticals (REGN) has been moving within a mixed performance range, with a 1 day return of about a 1% decline, a 7 day gain of 3.4%, a month decline of 5.6%, and a past 3 months gain of 16.
